The U.S. Food and Drug Administration approved Eli Lilly and Co’s migraine drug, Reyvow, Reuters reported.

The drug has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults.

Lilly acquired Reyvow, formerly called lasmiditan, in a deal here worth about $960 million when it bought CoLucid Pharmaceuticals Inc in early 2017. Lasmiditan was first developed at Lilly, but later licensed out to CoLucid in 2005.

The FDA advises patients not to drive or operate machinery for at least eight hours after taking Reyvow, as the drug causes dizziness and sedation.